Weโre thrilled to announce the extension of our Seed round toย ๐๐๐ 6.1 ๐ฆ๐ข๐ฅ๐ฅ๐ข๐จ๐ง, with Zรผrcher Kantonalbank joining our investor syndicate alongside Verve Ventures, Nina Capital, NovaCapital, and CADFEM International GmbH. This funding will accelerate our journey towardย ๐.๐. ๐ซ๐๐ ๐ฎ๐ฅ๐๐ญ๐จ๐ซ๐ฒ ๐๐ฉ๐ฉ๐ซ๐จ๐ฏ๐๐ฅ, the launch of our second-generationย ๐๐๐ฅ๐ฅ๐ฎ๐ฅ๐๐ซ๐ข๐ฌยฎย platform, and deeper commercial collaborations.
Our mission is toย ๐ญ๐ซ๐๐ง๐ฌ๐๐จ๐ซ๐ฆ ๐ซ๐๐ญ๐ข๐ง๐๐ฅ ๐๐ข๐๐ ๐ง๐จ๐ฌ๐ญ๐ข๐๐ฌย through AI-powered imaging that reaches theย ๐๐๐ฅ๐ฅ๐ฎ๐ฅ๐๐ซ ๐ฅ๐๐ฏ๐๐ฅ, enabling detection of diseases likeย ๐๐๐ ๐๐๐ซ๐ฅ๐ข๐๐ซ. With overย 1,000 ๐ฉ๐๐ญ๐ข๐๐ง๐ญ๐ฌ ๐ฌ๐๐๐ง๐ง๐๐ย andย 18,000+ ๐ซ๐๐ญ๐ข๐ง๐๐ฅ ๐ข๐ฆ๐๐ ๐๐ฌ ๐๐ง๐๐ฅ๐ฒ๐ณ๐๐, our technology is already trusted by leading institutions.
“This funding round marks a pivotal moment for EarlySight. With the support of our investors and new board members, weโre scaling up to bring vision-saving technology to millions.”ย โ Timothรฉ Laforest, CEO
๐ฃ Hear more from our board and management members:
๐น Peter Aggersbjerg (Vice-Chairman of the Board):
“Excited to share that I’m joining the Board of Directors at EarlySight as Vice Chair. EarlySight is pushing the boundaries of eye care with cutting-edge technology that enables earlier and more precise detection of retinal diseases. Itโs inspiring to be part of a team so deeply committed to improving vision health globally, and Iโm looking forward to contributing to the joint journey.”
๐น Andy Weymann MD MBAย (Independent Director):
“Excited to join the Board of Directors at EarlySight following their seed extension round! EarlySight’s Cellularis technology delivers high-resolution imaging that enables ophthalmologists to diagnose AMD and other retinal diseases much earlier โ leading to earlier treatment and better vision outcomes for millions of patients. Looking forward to supporting this mission to preserve sight through earlier detection.”
๐นย Prof. Francine Behar-Cohen (Co-founder, Board Member and Medical Advisor):
“Cellularis provides clinicians and clinical researchers with cellular imaging of the retina that is easy to use in clinical practice. This level of precision is particularly important for analyzing the pigment epithelium layer, where most retinal diseases originate but which, to date, has been difficult or impossible to examine. Thanks to this exploration, clinicians can not only better understand and monitor their patients, but also detect the early signs of disease. This will enable better monitoring of patients and preventive treatment to preserve vision. Cellularis is not just a promise, it is a reality that is now accessible to everyone.”
